BioCentury | Aug 22, 2020
Translation in Brief

IPD’s synthetic bio unlocks target combos for cell therapy; plus Merck’s oral STING agonist, Surrozen’s regenerative therapy and more

Synthetic switches aim T cells at cells expressing antigen combos David Baker’s team at University of Washington’s Institute for Protein Design published a study in Science showing its synthetic protein switches can direct T cells...
BioCentury | Mar 14, 2019
Financial News

TCG again backs Surrozen in $50M series B

Regenerative medicine company Surrozen raised a $50 Million series B round to move its optimized Wnt signaling mimetics into IND-enabling studies for an advanced liver disease yet to be determined. Surrozen Inc. (South San Francisco,...
BioCentury | Nov 28, 2018
Preclinical News

Placental organoid could improve preeclampsia therapies

A placenta-like organoid developed by a University of Cambridge team could improve understanding of maternal-fetal first-trimester disorders like preeclampsia and provide a model to study therapies to treat first-trimester complications. Challenges in preeclampsia and other...
BioCentury | Sep 21, 2018
Company News

Ahead of Ph Ib data, Celgene declines to exercise option to OncoMed bispecific

...T cell immunoreceptors with Ig and ITIM domains (TIGIT); rosmantuzumab is humanized IgG1 mAb targeting R-Spondin 3 (RSPO3)...
BioCentury | Jan 12, 2018
Clinical News

OncoMed's rosmantuzumab lacks clinical benefit in Phase I for solid tumors

...future medical conference. The company is discussing next steps for the humanized IgG1 mAb targeting R-Spondin 3 (RSPO3)...
...City, Calif. Product: Rosmantuzumab (OMP-131R10) Business: Cancer Molecular target: R-Spondin 3 (RSPO3) Description: Humanized IgG1 mAb targeting RSPO3...
...Safety and dose-limiting toxicities (DLTs) Status: Phase Ia/Ib data Milestone: NA Elizabeth S. Eaton OMP-131R10 rosmantuzumab Celgene Corp. OncoMed Pharmaceuticals Inc. R-Spondin 3 (RSPO3)...
BioCentury | Oct 31, 2017
Distillery Therapeutics

Transplant

INDICATION: Graft-versus-host disease (GvHD) Mouse studies suggest RSPO1 and DEFA1 could help prevent GvHD-induced gut dysbiosis. In a mouse model of GvHD, RSPO1 delivered before and after disease induction decreased dysbiosis and intestinal pathology compared...
BioCentury | Oct 27, 2017
Preclinical News

RSPO1 restores gut biome in GvHD

Researchers at Hokkaido University (Sapporo, Japan) and colleagues found that R-Spondin 1 ( RSPO1 ) stimulates differentiation of Paneth cells in the intestine, which secrete antimicrobial alpha defensins. The research, published in the Journal of Experimental Medicine...
BioCentury | May 31, 2017
Distillery Techniques

Disease models

TECHNOLOGY: 3-D models Mouse intestinal organoids could be used to model intestinal drug metabolism and toxicity. The organoids were generated by treating primary mouse crypt cells isolated from the small intestine with a cocktail of...
BioCentury | Jan 20, 2017
Clinical News

OMP-131R10: Interim Ph Ia/Ib data

...led to 5 cases of stable disease, of which 3 patients were determined to be "RSPO3...
...Redwood City, Calif. Product: OMP-131R10 Business: Cancer Molecular target: R-Spondin 3 (RSPO3) Description: Humanized IgG1 mAb targeting RSPO3...
...Endpoint: Safety and dose-limiting toxicities (DLTs) Status: Interim Phase Ia/Ib data Milestone: NA Julian Zhu OMP-131R10 OncoMed Pharmaceuticals Inc. R-Spondin 3 (RSPO3)...
BioCentury | Feb 4, 2016
Distillery Therapeutics

Therapeutics: R-Spondin 1 (RSPO1); RSPO2; RSPO3

...Cancer INDICATION: Cancer Patient sample and mouse studies suggest inhibiting RSPO1 , RSPO2 or RSPO3 could...
...highly expressed in ovarian tumors, RSPO2 was highly expressed in lung and colorectal tumors, and RSPO3...
...irinotecan decreased tumor growth. In patient-derived xenograft mouse models of ovarian or lung cancer, an anti-RSPO3...
Items per page:
1 - 10 of 29